Novo's revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8.1 billion. The ...
Pfizer agreed to buy the obesity startup Metsera for an enterprise value of about $4.9 billion as it seeks to catch up in a booming market after terminating the development of its own weight-loss pill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback